March 16, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 16, 2026

In the USA S&P 500 Healthcare stream, biotech and medtech firms dominate with mixed but stabilizing financials: revenues grew in devices (Smith & Nephew +6.1% YoY) while core sales declined in nutritionals (USANA -8.3% YoY), and biotechs narrowed losses (Rallybio -84% net loss YoY, HeartSciences -4% 9mo) amid pipeline catalysts. Cash positions strengthened significantly (Alto +5% to $177M funding into 2028, HeartSciences +209% to $3.4M), supported by $120M Alto raise and operational efficiencies (Rallybio opex -44% YoY). Broader filings reveal robust capital returns (SAIC $422M FY26 buybacks, Truist $10B new program, $5.2B returned 2025) and proxy season peaks with 10+ April 2026 meetings. Forward-looking optimism in healthcare via Alto's 1Q26/1H26 data/trials, Moderna's 8 oncology programs, Smith & Nephew's 6-7% CAGR RISE plan to 2028. Portfolio trends: 5/8 key HC firms improved cash/equity YoY, but margins compressed avg -150bps in 3/8 (USANA -370bps op); non-HC financials showed net income growth avg +25% YoY (SMARTFinancial +39%). Critical implications: Biotech catalysts cluster 1H26, signaling alpha in small/mid caps; monitor dilution from raises and weak bookings (SAIC Q4 btb 0.3x).

30 high priority20 medium50 total filings

March 13, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — March 13, 2026

Across 50 recent SEC filings from the USA S&P 500 Consumer Staples intelligence stream (with broader equity coverage), overarching themes include sustained capital returns via dividends and buybacks amid mixed FY2025/Q4 results, neutral-to-positive insider activity focused on planned diversification rather than opportunistic selling, and cautious forward-looking guidance with strategic reviews in non-core assets. Period-over-period trends reveal revenue growth in 7/15 detailed reporters (avg +12% YoY, e.g., monday.com +27%, CCEP +FX-neutral), but margin compression in 6/15 (avg -100bps, e.g., Velocity NIM -11bps, Aspen gross margin -2300bps), offset by efficiency gains (e.g., Fidelity D&D efficiency ratio -590bps to 60.3%). Critical developments feature CCEP's strong €20.9B revenue and €1B buyback completion signaling staples resilience, Walmart executives' 10b5-1 plans for routine sells up to $15M through 2029 (neutral conviction), and Petco/El Pollo Loco's modest sales growth (+3.6%/-2.5%) with profitability improvements. Portfolio-level patterns show 9/50 filings with dividends/buybacks (e.g., GIII $0.10, Ford 31.7M shares), indicating robust shareholder focus despite sector headwinds like flat same-store sales (El Pollo 0.1%). M&A/strategic processes (e.g., Barnwell oil/gas review, Monroe approvals) add alpha potential, while layoffs (Modular 29% workforce) flag cost pressures. Implications favor defensive staples plays with yields, monitoring catalysts like March 18 hearings and Q1 earnings.

26 high priority24 medium50 total filings

March 13, 2026·daily

S&P 500 Industrials Sector SEC Filings — March 13, 2026

Across 50 SEC filings for the USA S&P 500 Industrials intelligence stream (though spanning financials, energy, healthcare), bank 10-Ks dominate with resilient growth: ~12 banks averaged 4.5% YoY asset growth, 12% YoY NII increase, and 20bps NIM expansion (e.g., Red River +25% net income, Princeton +82%), offset by rising NPAs/provisions in 4 cases (avg +200%). Industrials shine with Venture Global's landmark $20.7B CP2 LNG financing (Phase 2 FID $8.6B, no equity needed, targeting 100+ MTPA capacity), Ducommun's record $824.7M revenue (+49% stock gain under VISION 2027), and ArcBest's $4B revenue/$86M returns despite freight weakness. Capital allocation trends positive: 5 dividends (GIII $0.10, Designer $0.05), buybacks (First Northern 1M shares thru Apr'26), stock div (First Northern 5% payable 3/25). Forward-looking catalysts include Better Home's Q1'26 loan vol guide $1.4-1.55B (post +56% YoY Q4), Tonix cash runway to Q1'27, and proxy meetings clustered Apr-May'26. Mixed sentiment (60% mixed/neutral) signals stability but credit watch; overweight NII-expanders like Fidelity D&D (+16.7% NII), avoid NPA outliers like Isabella (+553%). Portfolio implication: Industrials/financial hybrids offer defensive alpha via returns/M&A amid macro caution.

34 high priority16 medium50 total filings

March 13, 2026·daily

S&P 500 Energy Sector SEC Filings — March 13, 2026

Across these 7 diverse SEC filings (primarily real estate, banking, pharma/consumer health despite energy stream context), overarching themes include mixed financial performance with modest revenue growth offset by widening losses, impairments, and operational pressures in real estate entities. Period-over-period trends reveal revenue increases (BRT +1.5% YoY to $97M, Copper lease income +2% YoY to $96M, John Marshall NII +18.6% YoY) but declining profitability (BRT FY net loss to $(11.9M) from $(9.8M), Copper net income -36% YoY to $47M, same-store NOI flat/declining across BRT/Copper). Real estate-focused filings (BRT x2, Copper, Kaanapali) dominate with portfolio expansions/sales, higher debt costs, and impairments, while banking (John Marshall) shows robust +24% YoY net income growth to $21.2M and Haleon delivers clean audits. Capital allocation leans toward share repurchases (BRT 321k shares) and dividends (maintained $0.25 Q at BRT, $0.30 at John Marshall), but no insider trading patterns noted. Critical developments like Bioxytran's impairments/leadership changes signal distress, while land sales (Kaanapali +$10.3M gain) and bank asset growth (+4.4% to $2.33B) offer pockets of strength. Market implications: Heightened caution on real estate amid NOI declines and debt maturities, selective opportunities in growing financials; portfolio-level trend of margin compression (e.g., Copper NOI -7%, BRT AFFO flat) suggests broader sector vulnerability.

6 high priority1 medium7 total filings

March 13, 2026·daily

S&P 500 Financials Sector SEC Filings — March 13, 2026

Across 50 SEC filings purportedly from S&P 500 Financials (though spanning diverse sectors including pharma, hospitality, REITs, and banks), overarching themes include mixed sentiment with revenue growth in 12/20 reporting companies averaging +16% YoY (e.g., ONE Group +19.7%, Emerald +16.2%, Jefferson Capital +41.6%) offset by Q4 weakness, widening net losses (9/20 cases), and expense surges (e.g., Tonix SG&A +119%). True financials like Red River Bancshares (+25% net income, NIM +14bps to 3.38%), First Northern (+4.8% NII, NIM +17bps), Republic Bancorp (NPS +12% to 73.4), and Jefferson Capital (+45.8% net income) show resilience amid deposit declines elsewhere. Capital allocation leans shareholder-friendly with buybacks (News Corp $1B program, Emerald $17.5M repurchased, First Northern 1M+ shares authorized) and dividends (Emerald doubled to $0.06/share, BRT $0.25 Q). Insider activity limited to routine Walmart 10b5-1 plans (e.g., McMillon 155k shares). Forward-looking guidance optimistic for 2026 (ONE Group +4-6% rev, Emerald +6-7%), but risks from auditor changes (Amplify material weakness), lawsuits (Scilex fraud claims), and M&A approvals (Signing Day closes March 16). Portfolio-level: margin expansion in banks (3/4 improved), but REITs/others flat NOI; actionable now on catalysts like March 16-18 events.

30 high priority20 medium50 total filings

March 13, 2026·daily

S&P 500 Technology Sector SEC Filings — March 13, 2026

Across 20 SEC filings from the USA S&P 500 Technology stream (including adjacent financials/tech enablers), overarching themes include mixed financial performance in community banks with net interest margin (NIM) expansions averaging +20 bps YoY in 3/5 reporters offsetting non-interest income declines (e.g., Chemung -65.8%), aggressive capital returns via buybacks and dividends, positive proxy outcomes with strong approvals, and strategic M&A/debt issuances signaling growth confidence. Period-over-period trends show NII growth averaging +8% YoY (First Northern +4.8%, Chemung +17.7%, NorthEast -2%), but net income declines in 4/8 reporters (Chemung -36.2%, NorthEast -5.65%); tech highlights feature Salesforce's $25B debt-for-buybacks and Intuitive Surgical's leadership transition. Critical developments: Esquire-Signature $350M accretive merger (20-25% 2027 EPS acc.), Aditxt's $36M oncology acquisition, and MultiSensor AI's $60M ATM for growth capital. Portfolio-level patterns reveal shareholder-friendly capital allocation (buybacks in 3 firms, stock dividend), proxy successes (5/5 positive), but deposit declines (First Northern -7.3%) and revenue softness (RideNow -10.5% YoY) flag liquidity pressures. Tech sector shows conviction via debt-funded returns and M&A into AI/oncology, positioning for catalysts like Q3 2026 deal closes.

16 high priority4 medium20 total filings

March 13, 2026·daily

Nasdaq 100 Stocks SEC Filings — March 13, 2026

Across 19 filings from NASDAQ-100 related entities, community banks dominate with mixed 2025 results: net income declined YoY in all three (First Northern flat assets, Chemung -36.2% to $15.1M due to $17.5M securities loss offset by NII +17.7%, NorthEast -5.65% to $44.4M with NIM contracting -37bps), though NIM expanded in two (+17bps First Northern, +50bps Chemung) amid deposit declines (-7.3% First Northern). Positive corporate governance shines with overwhelming AGM approvals (Adient, Applied Materials, Ducommun record $824.7M rev +49% stock gain), leadership transitions (Intuitive Surgical CEO change), and capital raises (Amazon $37B notes for $36.8B net proceeds, NexMetals cash +551% to $39.8M post $80M financing). Biotech M&A/licensing active (Aditxt $36M Ignite acquisition targeting $3B market, AC Immune Takeda deal up to $2.1B milestones). Capital allocation favors shareholders via repurchases (First Northern 1M+ shares thru Apr 2026), stock div (5% First Northern), retention RSUs/awards (Adient $500K, Optimum $9.4M DCAs). Portfolio trend: financials show resilient NII growth (avg +8.8% YoY) despite one-offs, tech/industrials bullish on strategy execution. Key implication: Favor banks with NIM expansion and buybacks; monitor biotech catalysts amid loss risks.

13 high priority6 medium19 total filings

March 13, 2026·daily

Dow Jones 30 Stocks SEC Filings — March 13, 2026

Across 50 SEC filings from March 13, 2026, primarily regional banks and select energy/financial firms (despite DJ30 stream focus, data spans broader US blue-chips and mid-caps), FY2025 10-Ks reveal mixed resilience: 9/15 banks reported asset growth averaging 6-62% YoY (e.g., ChoiceOne +62%), NIM expansions in 7/15 (avg +20bps, e.g., Red River +14% to 3.38%), but provisions spiked sharply in outliers (ChoiceOne +2,367% to $14.8M). Energy sector shines with accretive M&A (Battalion Oil adds 30 drilling locations) and mega-financings (Venture Global $20.7B CP2 LNG FID). Capital allocation tilts shareholder-friendly (buybacks/dividends in CCEP €1B, First Northern 1M+ shares, Universal $0.105/share), amid neutral insider plans (Walmart exec 10b5-1 sales for diversification). Forward catalysts cluster in April-May AGMs (10+ meetings) and deadlines (Olenox registration Apr 11); sentiments mixed/neutral dominate (28/50), with positive outliers in growth stories. Portfolio implication: overweight regional banks with NIM tailwinds/strong ROE (Red River 12.58%), monitor provision risks; energy M&A offers alpha amid LNG demand.

38 high priority12 medium50 total filings

March 13, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 13, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (heavily skewed toward financials, retail/auto/entertainment), FY2025 results show mixed trends with robust revenue/NII growth averaging +30-50% YoY in outperformers like Jefferson Capital (+41.6%), Velocity Financial (+69% Q4 net income), and Better Home & Finance (+52% revenues), but widespread profitability erosion via compressed ROA/ROE (e.g., CHOICEONE ROA -31bps to 0.69%), exploding provisions (CHOICEONE +2367% to $14.8M), and rising expenses. Capital allocation leans bullish with buybacks (Ford 31.7M shares, CCEP €1B completed, Amazon/Salesforce debt-funded repurchases), stock dividends (First Northern 5%), and M&A (IF Bancorp merger delisting, Burke & Herbert board changes). Consumer discretionary standouts include Ford's anti-dilutive buyback, Walmart insider diversification plans (neutral), and Amazon's $37B notes for buybacks; entertainment sees director exits (Six Flags). Forward catalysts cluster in Q1-Q2 2026 (Better Home $1.4-1.55B Q1 volume, breakeven Q3), with risks from auditor changes (Amplify, Black Rock Coffee material weaknesses) and liquidity strains (Maris Tech substantial doubt). Portfolio implication: Favor growth financials with NIM expansion (First Northern +17bps, Fidelity D&D +16.7% NII) over deteriorating ones; monitor consumer buybacks for conviction.

36 high priority14 medium50 total filings

March 13, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 13, 2026

Across 48 SEC filings from the USA S&P 500 Healthcare stream (with heavy financial sector overlap), overarching themes include mixed financial performance in regional banks with net interest margin (NIM) expansions averaging +50bps YoY in 5/9 reporting banks (e.g., ChoiceOne +66bps to 3.61%, Norwood +58bps to 3.49%) offset by ROE declines in 4/7 (avg -300bps) due to higher provisions and expenses; healthcare firms show leadership transitions signaling continuity (Cigna CEO change July 2026, Intuitive Surgical CEO April 2026). Period-over-period trends reveal revenue growth in 6/15 detailed firms (avg +25% YoY, e.g., Norwood NII +26%) but net income volatility (wins like Franklin +91%, losses like Harvard Bioscience -$56.7M due to $48M goodwill impairment). Capital allocation leans shareholder-friendly with buybacks (CCEP €1B completed, News Corp $1B ongoing, Franklin 6,500 shares repurchased) and dividends (NewtekOne $0.19/share Q2 2026, SAIC $0.37/share). Healthcare-specific signals include positive proxy sentiments for Abbott and Intuitive Surgical, while Scilex's lawsuit adds sector litigation risk. Portfolio-level: 12/48 mixed sentiment filings highlight integration/M&A pressures (Esquire-Signature $350M deal 20-25% accretive), with upcoming AGMs (April 2026 cluster) as catalysts. Implications: Favor NIM expanders with strong capital returns; monitor healthcare leadership for execution risks.

31 high priority17 medium48 total filings

March 12, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — March 12, 2026

Across 50 diverse SEC filings (despite Consumer Staples focus, spanning tech, biotech, industrials, and media), period-over-period trends reveal mixed revenue performance with 14 companies showing YoY growth >10% (e.g., Angel Studios +233%, SentinelOne +22%, GE Aerospace +18%) versus 16 with declines >10% (e.g., Limoneira -47%, Funko -13.5%, Surf Air -11%), averaging ~ -2% YoY revenue change amid margin pressures (8/20 10-Ks reported EBITDA/margin contraction avg -150bps) but cash flow improvements in 10 cases (e.g., Kodak op cash $480M vs -$7M). Capital allocation leans defensive with buybacks/dividends in 7 firms (e.g., Constellium $300M program, G-III $54M returns) and debt raises/refinancings in 9 (e.g., Keurig $2.55B+$3B notes for JDE Peet’s M&A). Forward-looking data flags 12 catalysts like SentinelOne FY27 rev guide $1.195-1.205B and Surf Air 20-30% 2026 growth, but risks dominate with widening losses in 15 firms (avg +40% YoY) and dilution/delisting threats. Portfolio-level patterns show resilience in services/backlog growth (GE $190B backlog) contrasting consumer weakness; actionable now: favor cash-rich outperformers like GE/Velocity, avoid high-debt loss-makers like Ascend Wellness. Consumer Staples subset (Colgate, Keurig) neutral on board changes/debt for growth.

29 high priority21 medium50 total filings

March 12, 2026·daily

S&P 500 Industrials Sector SEC Filings — March 12, 2026

Across the 50 SEC filings dated March 12, 2026, for the 'USA S&P 500 Industrials' stream (though spanning diverse sectors), sentiment is mixed in 60% of cases, with revenue trends showing declines in 18/30 reporting companies averaging -6% YoY (e.g., WM Tech -5.3%, Bath & Body Works -0.2%, Stoneridge segments -6-7%), offset by hyper-growth outliers like Abacus Global +110% FY2025 and Angel Studios +233%. Profitability exhibits resilience via turnarounds (Bimini Capital FY NI $5.8M from -$1.3M, Blue Ridge $10.7M from -$15.4M) and margin expansions (Identiv Q4 gross +33pts to 18.1%, National Beverage op income +1.1%). Capital allocation prioritizes returns with 8 instances of dividends/buybacks (Abacus $0.20/share + $20M repurchase, Bimini $2.5M plan) and debt raises for M&A (CACI $500M notes, Longeveron $30M placement). Industrials standouts like GE Aerospace deliver +18% YoY revenue to $45.9B, +38% adj EPS, $190B backlog. Forward guidance is cautious (WM Tech Q1 mid-high single-digit decline seq from Q4 $43.1M), but positive catalysts include Abacus FY26 NI $96-104M and Longeveron ELPIS II readout 3Q26. Risks cluster around asset quality (Pioneer NPA x2 to $11.3M), impairments ($110M Health Catalyst), and restatements (Genie Energy). Implications: Favor selective longs in growth/turnarounds, monitor bank NIM compression and proxy outcomes.

32 high priority18 medium50 total filings

March 12, 2026·daily

S&P 500 Energy Sector SEC Filings — March 12, 2026

Across the six S&P 500 Energy stream filings (with some adjacent sectors), overarching themes include YoY revenue and EBITDA growth in energy producers like Hallador Energy (+16% revenue, 3x EBITDA) contrasting with QoQ weaknesses (e.g., Hallador Q4 -30% revenue) and mixed M&A/financing activity; Devon Energy's $TBD Coterra acquisition signals consolidation in oil/gas, while non-core filings highlight executive stability and micro-cap dilutions. Portfolio-level trends show 3/6 companies with YoY revenue surges (Hallador +16-19%, Orchestra +1,169%, Coal +9%) but per-unit pricing declines (Hallador electric -4%, coal -2%) and customer losses, alongside forward-contracted revenues providing visibility ($543-867M through 2029 for Hallador). Critical developments: Hallador's $120M credit facility and Merom gas expansion application bolster growth, Devon's Q2 2026 merger close offers synergies, but regulatory risks (EPA MATS) and dilution loom. Sector implications point to transition plays (coal-to-gas) amid volatility, with positive capital access but execution risks in Q4 results and deals.

5 high priority1 medium6 total filings

March 12, 2026·daily

S&P 500 Financials Sector SEC Filings — March 12, 2026

Across 50 SEC filings from diverse S&P 500 Financials-linked entities (including banks like Citizens Financial Services, asset managers like AllianceBernstein and Eagle Point, and broader financial services), sentiments are predominantly mixed or neutral, with 12/50 showing positive tilts driven by capital returns and select growth. Period-over-period trends reveal robust NII expansion in financials (e.g., CZFS +13.3% YoY to $99.1M, NIM to 3.50% from 3.13%; Velocity loans UPB +28% YoY to $6.5B, ROE to 17.5%), contrasted by portfolio declines (CION investments -4% to $1.81B, yield to 9.15% from 10.96%) and revenue drops in non-core (ProFrac -11% to $1.94B, Vivid Seats GOV -31% to $2.7B). Capital allocation shines with buyback expansions (Ibotta +$100M to $400M, KLA new $7B program) and dividend hikes (Deutsche Bank to €1.00/share +47%, KLA +21% to $2.30), signaling management conviction amid insider pledges (CZFS directors pledged 14-73% of holdings). Forward-looking data flags Q1 2026 softness (ProFrac EBITDA hit $8-12M weather) but upside catalysts like Gyre's $300M Cullgen acquisition (close Q2 2026) and multiple April AGMs. Portfolio-level, 6/10 financials show NIM/ROE gains vs. sector drags from impairments/losses, implying selective rotation into growing lenders while monitoring buyback-funded returns.

26 high priority24 medium50 total filings

March 12, 2026·daily

S&P 500 Technology Sector SEC Filings — March 12, 2026

Across 21 SEC filings in the USA S&P 500 Technology stream (including adjacent biotech and financials for context), overarching themes include clinical pipeline momentum in biotechs amid persistent cash burns, aggressive capital returns in semiconductors, record revenue growth in software leaders, and M&A consolidation in financials. Period-over-period trends show revenue expansion in Adobe (+12% YoY to $6.40B) and ACNB (+47.1% NII), contrasting sharp declines in Lyell (-41% YoY revenue) and Saga (-5.1% FY revenue), with net losses narrowing in biotechs (Adicet flat at $116.8M, Lyell -20% to $274.4M) but cash positions eroding (Adicet -31% to $38.9M, Lyell -43% to $60.2M). Critical developments feature KLA's 21% dividend hike to $2.30/share and $7B buyback authorization signaling strong conviction, Adobe's AI ARR tripling despite CEO transition, and Esquire-Signature merger at 2.630x exchange ratio. Portfolio-level patterns reveal 4/6 tech filings bullish on capital allocation/growth (KLA, Adobe, ADI, Salesforce ASR), mixed biotech sentiment (2/4 with clinical wins but burns), and neutral proxies. Implications point to selective opportunities in semis/software catalysts, caution on biotech runway, and M&A alpha in consolidations.

12 high priority9 medium21 total filings

March 12, 2026·daily

Nasdaq 100 Stocks SEC Filings — March 12, 2026

Across 21 NASDAQ-100 related filings from March 12, 2026, dominant themes include biotech firms (Adicet Bio, Lyell Immunopharma) reporting flat-to-improved net losses amid clinical advancements and extended cash runways into 2027, contrasted by revenue declines in smaller entities like Liquidmetal (-8.8% YoY) and Saga Communications (-5.1% FY2025). Adobe delivered standout Q1 FY2026 results with 12% YoY revenue growth to $6.40B and reaffirmed FY guidance, though CEO transition introduces uncertainty. Proxy season is in full swing with positive shareholder approvals at Analog Devices (93-99% support) and routine filings for Charter, CHCT, Metallus, and funds, signaling governance stability. Aggregate period trends show mixed revenue performance (3/7 financial reporters grew YoY, avg +4% where positive; 4 declined avg -7%), persistent operating losses in biotechs/healthcare (avg net loss improvement +10% YoY), and capital allocation favoring dividends/buybacks in Saga ($2.5M repurchases) and Metallus ($13.1M). M&A/debt activity via Keurig's $5.55B notes for JDE Peet's acquisition highlights leverage risks, while shelf registrations (Adicet S-3 $250M) flag potential dilution. Portfolio implications favor monitoring biotech catalysts and Adobe momentum, with caution on cash-intensive small caps.

9 high priority12 medium21 total filings

March 12, 2026·daily

Dow Jones 30 Stocks SEC Filings — March 12, 2026

Across 50 SEC filings from diverse US companies (with DJ30 relevance via blue-chips like Salesforce, Colgate-Palmolive, Analog Devices), mixed financial results dominate FY2025/Q1 2026 reporting, with 12/20 10-K/10-Q filings showing revenue growth averaging +25% YoY in outperformers (e.g., Orrstown +110% implied, Abacus +110%) but declines in 8/20 averaging -12% (e.g., Funko -13.5%, LivePerson -22%). Banks/financials (9 filings) exhibit strong balance sheet expansion (avg assets +15%, loans +15%) but NIM compression (-7 bps avg) and rising provisions signal credit stress. Capital allocation leans positive with dividends/buybacks in 6 firms (e.g., Abacus $0.20/share + $20M repurchase) amid $100M+ raises (Longeveron $30M, Kosmos 112M shares). Forward guidance mixed: raises in Abacus ($96-104M), cuts in LivePerson (-15-20% FY26). Resignations/impairments flag risks (Vestand, Health Catalyst $110M goodwill hit), while M&A/litigation (Archer vs Joby, Non Invasive merger) adds volatility. Upcoming April 2026 AGMs (10+ filings) offer voting catalysts; portfolio implication: overweight resilient banks, avoid retail distress.

34 high priority16 medium50 total filings

March 12, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 12, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary stream (retail, automotive, hotels, entertainment, with financial/crypto outliers), sentiment is predominantly mixed (24/50), with positive in 10 and negative in 6; key trends include revenue declines averaging -8% YoY in consumer-facing firms like Funko (-13.5%), Surf Air (-11%), and Lifetime Brands (-5.1%), offset by growth in food/retail like Once Upon a Farm (+53.5% FY sales) and Weis Markets (+3.5%). Crypto ETFs (Grayscale XRP/Solana/Chainlink/Dogecoin, Bitwise ETH) show explosive AUM growth (56-2200% YoY) via share issuances but NAV/share drops 15-40% from unrealized crypto losses. Financials exhibit asset/loan growth (Orrstown +25.7% assets, Citizens NII +13.3%) and NIM expansions (+37bps Citizens), with steady dividends. Forward guidance bullish in select (Once Upon a Farm 25-29% 2026 sales growth, Surf Air 20-30%), but impairments/net losses common (Funko op loss $46M, Braemar hotel net -$13M). Capital allocation leans to dividends/buybacks (Omega Flex div +0.7%, Orrstown accretion), M&A active (Laird Navitas $38.5M). Implications: Tactical buys in growth outliers amid sector caution, watch Q1 2026 catalysts.

37 high priority13 medium50 total filings

March 12, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 12, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (including cross-sector context from financials and industrials), overarching themes reveal mixed financial performance with robust revenue/asset growth in 12/50 companies (avg +25% YoY where reported, e.g., Orrstown +25.7%, Acacia +133%) offset by margin compression in 8/50 (avg -150bps, e.g., Lennar gross margin 15.2% vs 18.7%) and widening losses in biotechs/financials (e.g., MBX +40% YoY loss). Healthcare-specific highlights include positive clinical catalysts (Solid Biosciences robust Phase 1/2 data, Precision Bio Q4 rev +5600% YoY to $34.2M) amid risks like Stryker's cyber disruption and Cassava's FDA hold. Capital allocation leans defensive with debt retirements (B. Riley $37.9M), repurchases (Lennar $237M, CION $5.2M), and stable dividends (CION $0.36/share), while M&A activity signals consolidation (Esquire-Signature merger at 2.63x exchange). Forward-looking data flags 15+ catalysts into H2 2026, including trial readouts and guidances, positioning selective biotechs for alpha despite sector net losses (9/12 healthcare filers). Portfolio-level trends show improving ROE in outperformers (Velocity +310bps to 17.5%) but rising provisions/NPLs in laggards, urging focus on clinical momentum over broad financials.

28 high priority22 medium50 total filings

March 11, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — March 11, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader cross-sector context), sentiment is predominantly mixed (24/50 filings), reflecting resilient revenue growth in staples outliers like Costco (+9.3% YoY Q2 revenue to $69.6B) amid declines in core players like Campbell's (-5% YoY Q2 net sales to $2.6B, lowered FY2026 guidance). Portfolio-level trends show 12/28 quantifiable revenue reporters with YoY growth averaging +24% (e.g., Oracle +22%, Marvell +42%), but 10 with declines averaging -12% (e.g., Nuwellis -5.4%, Campbell's -4.5% six-month); margins compressed in 8/15 (avg -150bps, e.g., Travelzoo 80.3% vs 87.5%), offset by expansions in 5 (e.g., Marvell +970bps to 51%). Capital allocation leans shareholder-friendly with dividends (ICL $232M, 3.1% yield; Pangaea $0.05/share) and buybacks (Campbell's $172M remaining; Core Molding +$6.5M to $7.5M total), while M&A/divestitures active (Elutia $88M BioEnvelope sale; Katapult pending merger). Forward-looking data flags lowered guidance (Campbell's organic sales -2% to flat) but optimistic catalysts (Netskope FY2027 revenue $870-876M; Elutia FDA 2H26). Proxy-heavy filings (12/50) signal governance focus ahead of April AGMs, with no major insider selling patterns but positive buyback conviction. Implications: Staples face volume headwinds/storm impacts, favor growth outliers like Costco; monitor margin trends and Q1 2026 catalysts for portfolio rotation.

26 high priority24 medium50 total filings

← All geographies